|
- 2025 AIM Advocacy Forum | Alzheimer’s Association
The Alzheimer's Impact Movement (AIM) Advocacy Forum is the nation's premier Alzheimer's disease advocacy event Volunteer advocates from across the United States come together to make the case to federal policymakers to advance policies to improve the lives of all individuals affected by Alzheimer’s and all other dementia Attendance at this year's event is by direct invitation
- New Alzheimers discoveries unveiled at the 2025 Alzheimers . . .
Alzheimer's Association national site – information on Alzheimer's disease and dementia symptoms, diagnosis, stages, treatment, care and support resources
- AAIC 2025 Highlights for a General Audience
In addition to these highlights, AAIC® For All is a new extension of AAIC A no-cost, single-day event, AAIC For All is an opportunity for clinicians and interested community members to learn about the latest research findings AAIC For All takes place on the final day of AAIC, so you will be among the first to hear about cutting-edge research announced at the conference
- 2025 AIM Advocacy Forum | Alzheimer’s Association
Join the 2025 Alzheimer’s Impact Movement Advocacy Forum Urge Congress to advance policy and improve the lives of individuals affected by dementia
- Alzheimers Association Welcomes FDA Approval of Aducanumab
The Alzheimer’s Association enthusiastically welcomes today’s historic FDA approval of aducanumab (Biogen Eisai) for treatment of Alzheimer’s disease
- FDA Advisory Committee Agrees on Donanemab Efficacy | alz. org
The Alzheimer’s Association welcomes the advisory committee’s unanimous finding that donanemab is effective for the treatment of early Alzheimer’s disease
- Alzheimers Association Statement on Gantenerumab Phase 3 Topline Data . . .
Alzheimer's Association national site – information on Alzheimer's disease and dementia symptoms, diagnosis, stages, treatment, care and support resources
- Lecanemab Approved for Treatment of Early Alzheimer’s | alz. org
Lecanemab (Leqembi™) has received accelerated approval as a treatment for early Alzheimer’s from the U S Food and Drug Administration
|
|
|